{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:10:22Z","timestamp":1735571422756,"version":"3.32.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,30]]},"DOI":"10.7759\/cureus.76622","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T14:47:56Z","timestamp":1735570076000},"source":"Crossref","is-referenced-by-count":0,"title":["Unraveling Histiocytic Disorders: Two Cases From Resource-Limited Settings"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Elbahoty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooran","family":"Soror","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar M","family":"Gad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Eldowik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia I","family":"Halwag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Elghandour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.177","article-title":"Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation","volume":"7","author":"Kemps PG","year":"2021","unstructured":"Kemps PG, Hebeda KM, Pals ST, et al.. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation. J Pathol Clin Res. 2021, 7:10-26. 10.1002\/cjp2.177","journal-title":"J Pathol Clin Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00307-9","article-title":"Histiocytic disorders","volume":"7","author":"McClain KL","year":"2021","unstructured":"McClain KL, Bigenwald C, Collin M, et al.. Histiocytic disorders. Nat Rev Dis Primers. 2021, 7:73. 10.1038\/s41572-021-00307-9","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12117","article-title":"Human dendritic cell subsets","volume":"140","author":"Collin M","year":"2013","unstructured":"Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology. 2013, 140:22-30. 10.1111\/imm.12117","journal-title":"Immunology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams M","year":"2014","unstructured":"Guilliams M, Ginhoux F, Jakubzick C, et al.. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014, 14:571-8. 10.1038\/nri3712","journal-title":"Nat Rev Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile JF","year":"2016","unstructured":"Emile JF, Abla O, Fraitag S, et al.. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016, 127:2672-81. 10.1182\/blood-2016-01-690636","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000934","article-title":"Langerhans cell histiocytosis","volume":"135","author":"Rodriguez-Galindo C","year":"2020","unstructured":"Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020, 135:1319-31. 10.1182\/blood.2019000934","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02989-8","article-title":"Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis","volume":"18","author":"Lang M","year":"2023","unstructured":"Lang M, Cai HC, Lin H, et al.. Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis. Orphanet J Rare Dis. 2023, 18:372. 10.1186\/s13023-023-02989-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal G","year":"2022","unstructured":"Goyal G, Tazi A, Go RS, et al.. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022, 139:2601-21. 10.1182\/blood.2021014343","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1607548","article-title":"Langerhans-cell histiocytosis","volume":"379","author":"Allen CE","year":"2018","unstructured":"Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018, 379:856-68. 10.1056\/NEJMra1607548","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01439-3","article-title":"Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis","volume":"36","author":"Chen J","year":"2022","unstructured":"Chen J, Zhao AL, Duan MH, et al.. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. Leukemia. 2022, 36:573-6. 10.1038\/s41375-021-01439-3","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-569301","article-title":"How I treat Langerhans cell histiocytosis","volume":"126","author":"Allen CE","year":"2015","unstructured":"Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015, 126:26-35. 10.1182\/blood-2014-12-569301","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02032-6","article-title":"Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease","volume":"37","author":"Chang L","year":"2023","unstructured":"Chang L, Qiao B, Cai H, et al.. Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia. 2023, 37:2297-300. 10.1038\/s41375-023-02032-6","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla O","year":"2018","unstructured":"Abla O, Jacobsen E, Picarsic J, et al.. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018, 131:2877-90. 10.1182\/blood-2018-03-839753","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219626","article-title":"Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease","volume":"105","author":"Goyal G","year":"2020","unstructured":"Goyal G, Ravindran A, Young JR, et al.. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020, 105:348-57. 10.3324\/haematol.2019.219626","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206733","article-title":"Rosai-Dorfman disease: an overview","volume":"73","author":"Bruce-Brand C","year":"2020","unstructured":"Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020, 73:697-705. 10.1136\/jclinpath-2020-206733","journal-title":"J Clin Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"6","author":"Chakraborty R","year":"2014","unstructured":"Chakraborty R, Hampton OA, Shen X, et al.. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014, 6:3007-15. 10.1182\/blood-2014-05-577825","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13261","article-title":"Diagnosis and management of diabetes insipidus for the internist: an update","volume":"290","author":"Christ-Crain M","year":"2021","unstructured":"Christ-Crain M, Winzeler B, Refardt J. Diagnosis and management of diabetes insipidus for the internist: an update. J Intern Med. 2021, 290:73-87. 10.1111\/joim.13261","journal-title":"J Intern Med"},{"key":"ref19","article-title":"Rosai-Dorfman disease: management of CNS and systemic involvement","volume":"10","author":"Cooper SL","year":"2012","unstructured":"Cooper SL, Jenrette JM. Rosai-Dorfman disease: management of CNS and systemic involvement. Clin Adv Hematol Oncol. 2012, 10:199-202.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2019.07.030","article-title":"Diagnosis and treatment of Langerhans cell histiocytosis with bone lesion in pediatric patient: a case report","volume":"45","author":"Kamal AF","year":"2019","unstructured":"Kamal AF, Luthfi AP. Diagnosis and treatment of Langerhans cell histiocytosis with bone lesion in pediatric patient: a case report. Ann Med Surg (Lond). 2019, 45:102-9. 10.1016\/j.amsu.2019.07.030","journal-title":"Ann Med Surg (Lond)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00311-1","article-title":"Histiocytosis","volume":"398","author":"Emile JF","year":"2021","unstructured":"Emile JF, Cohen-Aubart F, Collin M, et al.. Histiocytosis. Lancet. 2021, 398:157-70. 10.1016\/S0140-6736(21)00311-1","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26784","article-title":"Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas","volume":"65","author":"Yeh EA","year":"2018","unstructured":"Yeh EA, Greenberg J, Abla O, et al.. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer. 2018, 65:e26784. 10.1002\/pbc.26784","journal-title":"Pediatr Blood Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13817","article-title":"Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment","volume":"109","author":"Kobayashi M","year":"2018","unstructured":"Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018, 109:3707-13. 10.1111\/cas.13817","journal-title":"Cancer Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000531230","article-title":"Langerhans cell histiocytosis with good response to low-dose imatinib: case report and literature review","volume":"16","author":"Abdulgayoom M","year":"2023","unstructured":"Abdulgayoom M, Mudawi D, Lengyel Z, Abo Samra H, Alshurafa A, Yassin MA. Langerhans cell histiocytosis with good response to low-dose imatinib: case report and literature review. Case Rep Oncol. 2023, 16:511-8. 10.1159\/000531230","journal-title":"Case Rep Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt R","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, et al.. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013, 60:175-84. 10.1002\/pbc.24367","journal-title":"Pediatr Blood Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-024-00320-9","article-title":"New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline","volume":"6","author":"Weimar C","year":"2024","unstructured":"Weimar C, Beyer-Westendorf J, Bohmann FO, et al.. New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline. Neurol Res Pract. 2024, 6:23. 10.1186\/s42466-024-00320-9","journal-title":"Neurol Res Pract"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.57.477","article-title":"Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22). (Article in Japanese)","volume":"57","author":"Kawakami K","year":"2016","unstructured":"Kawakami K, Ito R, Kageyama Y, Nagaharu K, Yamaguchi T, Ito N. Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22). (Article in Japanese). Rinsho Ketsueki. 2016, 57:477-82. 10.11406\/rinketsu.57.477","journal-title":"Rinsho Ketsueki"},{"key":"ref28","article-title":"Cerebral venous thrombosis after first methotrexate administration by lumbar puncture in a patient with large B cell lymphoma","volume":"101","author":"Ben Kahla A","year":"2023","unstructured":"Ben Kahla A, Kassar O, Moalla K, Fakhfakh Y, Hentati Y, Elloumi M. Cerebral venous thrombosis after first methotrexate administration by lumbar puncture in a patient with large B cell lymphoma. Tunis Med. 2023, 101:648-50.","journal-title":"Tunis Med"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1097\/00004728-199403000-00025","article-title":"MR of intracranial Langerhans cell histiocytosis","volume":"18","author":"George JC","year":"1994","unstructured":"George JC, Edwards MK, Smith RR, Provisor AJ. MR of intracranial Langerhans cell histiocytosis. J Comput Assist Tomogr. 1994, 18:295-7.","journal-title":"J Comput Assist Tomogr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/088307380101600605","article-title":"Langerhans' cell histiocytosis presenting as intracranial hypertension","volume":"16","author":"Modan-Moses D","year":"2001","unstructured":"Modan-Moses D, Ben-Zee B, Feldman Z. Langerhans' cell histiocytosis presenting as intracranial hypertension. J Child Neurol. 2001, 16:414-6. 10.1177\/088307380101600605","journal-title":"J Child Neurol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9571400","article-title":"A report of Rosai-Dorfman disease in an adolescent","volume":"2022","author":"Amoako E","year":"2022","unstructured":"Amoako E, Danso KA, Akuaku RS, Ulzen-Appiah K. A report of Rosai-Dorfman disease in an adolescent. Case Rep Pediatr. 2022, 2022:9571400. 10.1155\/2022\/9571400","journal-title":"Case Rep Pediatr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-024-00015-9","article-title":"Pathologic characteristics of histiocytic and dendritic cell neoplasms","volume":"59","author":"Yoon SO","year":"2024","unstructured":"Yoon SO. Pathologic characteristics of histiocytic and dendritic cell neoplasms. Blood Res. 2024, 59:18. 10.1007\/s44313-024-00015-9","journal-title":"Blood Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7098","article-title":"Challenges in the histopathologic diagnosis of histiocytic neoplasms","volume":"19","author":"Rech KL","year":"2021","unstructured":"Rech KL, He R. Challenges in the histopathologic diagnosis of histiocytic neoplasms. J Natl Compr Canc Netw. 2021, 19:1305-11. 10.6004\/jnccn.2021.7098","journal-title":"J Natl Compr Canc Netw"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1173","article-title":"Rituximab in the treatment of Rosai-Dorfman syndrome with IgG4 disease","volume":"81","author":"Al-Kutubi H","year":"2019","unstructured":"Al-Kutubi H, Maheshwari M, Chan SA, Abdullah A. Rituximab in the treatment of Rosai-Dorfman syndrome with IgG4 disease. J Am Acad Dermatol. 2019, 81:AB269. 10.1016\/j.jaad.2019.06.1173","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091275","article-title":"Rituximab treatment in a child with Rosai-Dorfman disease and systemic lupus erythematosus","volume":"37","author":"Alqanatish JT","year":"2010","unstructured":"Alqanatish JT, Houghton K, Bond M, Senger C, Tucker LB. Rituximab treatment in a child with Rosai-Dorfman disease and systemic lupus erythematosus. J Rheumatol. 2010, 37:1783-4. 10.3899\/jrheum.091275","journal-title":"J Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-023-00569-8","article-title":"Treatment of Langerhans cell histiocytosis and histiocytic disorders: a focus on MAPK pathway inhibitors","volume":"25","author":"Geerlinks AV","year":"2023","unstructured":"Geerlinks AV, Abla O. Treatment of Langerhans cell histiocytosis and histiocytic disorders: a focus on MAPK pathway inhibitors. Paediatr Drugs. 2023, 25:399-409. 10.1007\/s40272-023-00569-8","journal-title":"Paediatr Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297044-unraveling-histiocytic-disorders-two-cases-from-resource-limited-settings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T14:47:58Z","timestamp":1735570078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297044-unraveling-histiocytic-disorders-two-cases-from-resource-limited-settings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.76622","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}